Over the past decades, stem cell transplantation has been recognized as very promising therapy for neurological diseases. Despite advances in medical and surgical intervention, post-stroke therapies remain scarce, which seriously affects the quality of life of patients. Stice, the UGA lead for CMaT, and industry partners like ArunA Biomedical, will develop tools and technologies for the consistent and low-cost production of high-quality living therapeutic cells that could revolutionize treatment for stroke, cancer, heart disease and other disorders.Ischemic stroke, with its high morbidity and mortality, is the most common cerebrovascular accident and results in severe neurological deficits. Researchers also plan to leverage collaborations with other institutions through the National Science Foundation Engineering Research Center for Cell Manufacturing Technologies, based at the Georgia Institute of Technology and supported by $20 million in NSF funding. The company has plans to expand this initiative beyond stroke for preclinical studies in epilepsy, traumatic brain and spinal cord injuries later this year. Today, ArunA's manufacturing process positions the company to produce AB126 exosomes at a scale to meet early clinical demand. Named as part of the 'stroke belt' region, Georgia continues to exceed the national average in stroke deaths, which is the third leading cause of death in the U.S., with more than 140,000 Americans dying each year, according to the Centers for Disease Control and Prevention.ĪrunA recently unveiled advances to the company's proprietary neural cell platform for the production of exosome manufacturing.
"Just days after stroke, we saw better mobility, improved balance and measurable behavioral benefits in treated animal models." "Until now, we had very little evidence specific to neural exosome treatment and the ability to improve motor function," said Stice. Outside of rodents, the results were replicated by Franklin West, associate professor of animal and dairy science, and fellow RBC members using a porcine model of stroke-the only one of its kind in the U.S.īased on these pre-clinical results, ArunA Biomedical plans to begin human studies in 2019, said Stice, who is also chief scientific officer of ArunA Biomedical.
"When packaged with therapeutics, these treatments can actually change cell progression and improve functional recovery."įollowing the administration of AB126, the researchers used MRI scans to measure brain atrophy rates in preclinical, age-matched stroke models, which showed an approximately 35 percent decrease in the size of injury and 50 percent reduction in brain tissue loss - something not observed acutely in previous studies of exosome treatment for stroke. Brooks Distinguished Professor in the College of Agricultural and Environmental Sciences. "This is truly exciting evidence, because exosomes provide a stealth-like characteristic, invisible even to the body's own defenses," said Stice, Georgia Research Alliance Eminent Scholar and D.W. Small in size, the tiny tubular shape of an exosome allows EV therapy to cross barriers that cells cannot. The research team led by UGA professor Steven Stice and Nasrul Hoda of Augusta University created a treatment called AB126 using extracellular vesicles (EV), fluid-filled structures known as exosomes, which are generated from human neural stem cells.įully able to cloak itself within the bloodstream, this type of regenerative EV therapy appears to be the most promising in overcoming the limitations of many cell therapies-with the ability for exosomes to carry and deliver multiple doses-as well as the ability to store and administer treatment.
0 kommentar(er)
